The FDA advisory hearing on OxyContin abuse risks became a public test of whether the drug’s potential for addiction had been adequately examined before and after approval. Art Van Zee, a rural physician confronting OxyContin’s effects in Southwest Virginia, asked regulators and prominent pain specialists to reckon with evidence about how the drug could be misused and with the absence of research on long-term risk. The exchange did not settle the argument over opioid treatment; it exposed how much of that argument rested on incomplete evidence and competing judgments about acceptable harm.

Background and stakes

Van Zee’s challenge drew on the application Purdue Pharma had submitted before OxyContin’s approval. His wife, Sue Ella Kobak, had given him a copy of the New Drug Application as a Christmas present in 2000. Its review described the consequences of crushing the tablets: the controlled-release mechanism could be defeated, and the drug released immediately. It also recorded withdrawal symptoms in several clinical-trial patients and reported that 68 percent of the oxycodone in one crushed tablet could be recovered after liquefying it for injection. Purdue later maintained that it had not known of the drug’s abuse problems until February 2000, but the application’s contents made the risks legible in the company’s own pre-approval record.

The significance of the hearing was therefore not limited to whether OxyContin could relieve pain. It concerned how addiction risk had been assessed, how claims about rare addiction could be applied outside the settings from which they originated, and whether the available research could support confident assurances about long-term use. Van Zee brought the company’s own application into a debate in which the gap between broad claims and direct evidence was central.

Van Zee confronts the panel

In January 2002, Van Zee drove eight hours to Maryland to testify before an advisory committee of the U.S. Food and Drug Administration. He wore his only suit and a Jerry Garcia necktie his mother had given him. Across from him were Purdue executives and leading pain-management specialists, most of whom acknowledged that they were or had been paid speakers for Purdue. Van Zee was outnumbered nineteen to one. For a physician unaccustomed to public speaking, the setting was intimidating, but he regarded testifying as a responsibility.

The opposing case, as represented by a Purdue-funded speaker, held that concern about abuse by a few should not restrict the potential health benefits for many people in pain. It also framed insufficient treatment of pain as a major drug-abuse problem in its own right. That position brought the hearing’s central tension into focus: the prospect of undertreating pain was set against the possibility that expanded opioid use would expose more patients to addiction. The disagreement was not simply between treating pain and ignoring it; it was over how to weigh uncertain risks against asserted benefits, and whose experience would count in making that calculation.

Questions about risk and missing evidence

The next morning, Van Zee spoke with Russell Portenoy, a prominent pain specialist, and asked what level of addiction risk he considered acceptable for OxyContin. Van Zee challenged reliance on a frequently repeated figure of less than one percent: it came from an older medical-journal letter, concerned a hospital setting, and did not establish the long-term risk for people taking opioids at home for chronic pain. The distinction mattered because evidence drawn from one context could not, by itself, answer a question about another.

Van Zee brought a map of OxyContin distribution to their discussion. It showed the overlap between elevated crime and drug abuse and areas such as Lee County, Virginia, where prescribing ran 300 to 600 percent above the national average. Portenoy responded that greater opioid availability could better meet the needs of patients with chronic pain. Van Zee pressed the issue by asking what level of collateral damage would be acceptable if the addiction risk were five or six percent, and whether tens of thousands of people might become addicted. Portenoy eventually walked away. The exchange made their disagreement concrete: a general case for wider access met a question about the potential human cost of that supply in places where prescribing was exceptionally high.

At the end of the 2002 hearing, Van Zee raised similar concerns with committee chairman Nathaniel Katz. He explained that he had spent months searching for studies of long-term abuse risk among people using pain medication. Katz told him that such studies did not exist. The answer shifted the problem from a dispute about competing estimates to a more basic evidentiary failure: the research needed to calculate long-term risk was absent. Van Zee then recognized that the detailed abuse analysis he had found was the one Purdue had conducted for its 1995 application—the same review that documented the amount of oxycodone recoverable from a crushed tablet.

Aftermath and significance

The forum concluded with experts urging the U.S. Food and Drug Administration to monitor abuse and addiction closely when new drugs reached the market. That recommendation acknowledged the need for continuing scrutiny, but it did not resolve what the hearing had exposed: regulators and clinicians were debating a powerful drug without the long-term studies that could clarify the risks for patients treated at home. The hearing placed the evidence gap alongside the drug’s documented vulnerability to manipulation and the sharply different views of how much risk was acceptable.

The episode also belonged to a larger debate over the institutions shaping opioid treatment. Subsequent reporting revealed private meetings between regulators and pharmaceutical executives, while reporting on pain-advocacy organizations documented industry funding alongside campaigns for broader long-term opioid use. A 2012 Senate investigation examined relationships involving those organizations, Purdue, and other companies, but its findings remained sealed in the Senate Finance Committee’s office. These later developments do not establish that the hearing itself caused any particular regulatory decision. They do show why Van Zee’s questions about evidence, influence, and oversight remained consequential: the public debate over OxyContin took place within a system in which research gaps and financial relationships could shape what decision-makers heard.

The hearing’s lasting force in the narrative rests on the contrast between certainty and uncertainty. Advocates for wider opioid treatment spoke to unmet pain, while Van Zee pointed to unusually high prescribing, the risks recorded in Purdue’s own application, and the missing studies needed to quantify long-term harm. His challenge did not supply a complete answer. It made the unanswered questions—and the consequences of treating them as settled—impossible to overlook.